10 products added to the Discount Not Deducted (DND) list from May 2024

Community Pharmacy England on behalf of pharmacy owners made further applications to the Department of Health and Social Care (DHSC) and the NHS Business Services Authority (NHSBSA), resulting in a further 10 new products being added to the ‘Drugs for which Discount is Not Deducted’ (DND) list from 1 May 2024. This takes the total number of products granted DND status to over 630 products following checks made by our Dispensing & Supply team over the past 3 years to ensure fair reimbursement for pharmacy owners.

Click here to view the 10 products added to DND list on 1 May 2024:

  • Dexcom One+ Sensor
  • Levorol 6.25mg tablets
  • Semaglutide 3mg tablets
  • Semaglutide 7mg tablets
  • Semaglutide 14mg tablets
  • Tinzaparin sodium 10,000units/0.5ml solution for injection pre-filled syringes
  • Tinzaparin sodium 14,000units/0.7ml solution for injection pre-filled syringes
  • Tinzaparin sodium 18,000units/0.9ml solution for injection pre-filled syringes
  • Tinzaparin sodium 20,000units/2ml solution for injection vials
  • Tinzaparin sodium 40,000units/2ml solution for injection vials

For a list of all the monthly changes to the DND status of products please see the following page Notice of changes to discount not deducted (DND) status of products.


Background

The DND list is updated monthly by the DHSC and includes grouped and individual items. Individual items are separately listed in Part II of the Drug Tariff. Any items covered by the ‘Group Items’ heading are not listed again individually in Part II. Pharmacy owners can also check the Actual Medicinal Product (AMP) listing on Dictionary of Medicines and Devices (dm+d) to identify whether a product meets the DND criteria (see below).

Group items

Any products that are covered by one or more of the Group items categories below are reimbursed without any discount deduction applied.

  • Cold Chain Storage (ALL)
  • Schedule 1, 2 or 3 Controlled Drugs: Products containing drugs listed in Schedules 1, 2 and 3 of the Misuse of Drugs Regulation 2001
  • Cytotoxic or Cytostatic item (ALL):
  • Immunoglobulins (ALL)
  • Insulins for injection (ALL)
  • Vaccines and antisera (ALL)
  • Unlicensed medicines: ‘Specials’ not listed in Part VIIIB where the product has been sourced from a supplier holding a MHRA specials or importers licence (prescriptions must be endorsed with invoice price less discount/rebate)
  • Hazardous chemicals

Individual items  

Products that do not are covered by one or more of the Group item categories above must fulfil all three of the following criteria to qualify for entry to the DND list.

  • the manufacturer(s), AAH and Alliance do not offer pharmacy owners a discount
  • fewer than 500,000 items per year are dispensed of the product
  • average net ingredient cost (NIC) per item is more than £50

We will continue our work to assess whether other drugs and appliances fulfil the current DND entry requirements under either the ‘Group’ and ‘Individual item’ criteria and make applications to NHSBSA and DHSC, on behalf of pharmacy owners accordingly.

If a product is currently subject to the discount deduction scale and you believe that it should be added to DND list based on the criteria specified above, please contact the our Dispensing and Supply Team by emailing ds.team@cpe.org.uk who will investigate whether the product meets the relevant DND criteria and make an application to the DHSC and NHSBSA, as appropriate.

For further information on how discount deduction works, click here.

Support the call for more funding by recording information about the informal advice you provide to patients over just one day.

Click Here